IL255449B2 - Inhibitors of histone deacetylase and their compositions and methods of use - Google Patents

Inhibitors of histone deacetylase and their compositions and methods of use

Info

Publication number
IL255449B2
IL255449B2 IL255449A IL25544917A IL255449B2 IL 255449 B2 IL255449 B2 IL 255449B2 IL 255449 A IL255449 A IL 255449A IL 25544917 A IL25544917 A IL 25544917A IL 255449 B2 IL255449 B2 IL 255449B2
Authority
IL
Israel
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound
oxadiazol
alkyl
Prior art date
Application number
IL255449A
Other languages
English (en)
Hebrew (he)
Other versions
IL255449B1 (en
IL255449A0 (en
Inventor
Dominguez Celia
C Maillard Michel
Breccia Perla
F Haughan Alan
E Jarvis Rebecca
A Luckhurst Christopher
A Saville-Stones Elizabeth
J Stott Andrew
VAN DE POEL Amanda
Wall Michael
Wishart Grant
Original Assignee
Chdi Foundation Inc
Dominguez Celia
C Maillard Michel
Breccia Perla
F Haughan Alan
E Jarvis Rebecca
A Luckhurst Christopher
Elizabeth A Saville Stones
J Stott Andrew
VAN DE POEL Amanda
Wall Michael
Wishart Grant
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chdi Foundation Inc, Dominguez Celia, C Maillard Michel, Breccia Perla, F Haughan Alan, E Jarvis Rebecca, A Luckhurst Christopher, Elizabeth A Saville Stones, J Stott Andrew, VAN DE POEL Amanda, Wall Michael, Wishart Grant filed Critical Chdi Foundation Inc
Publication of IL255449A0 publication Critical patent/IL255449A0/en
Publication of IL255449B1 publication Critical patent/IL255449B1/en
Publication of IL255449B2 publication Critical patent/IL255449B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
IL255449A 2015-05-07 2017-11-06 Inhibitors of histone deacetylase and their compositions and methods of use IL255449B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158379P 2015-05-07 2015-05-07
PCT/US2016/031329 WO2016179550A1 (en) 2015-05-07 2016-05-06 Histone deacetylase inhibitors and compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
IL255449A0 IL255449A0 (en) 2017-12-31
IL255449B1 IL255449B1 (en) 2023-03-01
IL255449B2 true IL255449B2 (en) 2023-07-01

Family

ID=57218066

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255449A IL255449B2 (en) 2015-05-07 2017-11-06 Inhibitors of histone deacetylase and their compositions and methods of use

Country Status (12)

Country Link
US (2) US10047073B2 (enExample)
EP (1) EP3291809B1 (enExample)
JP (1) JP6782255B2 (enExample)
KR (1) KR20180002730A (enExample)
CN (1) CN107735087B (enExample)
AU (1) AU2016256917B2 (enExample)
BR (1) BR112017023710B1 (enExample)
CA (1) CA2984621C (enExample)
EA (1) EA035592B1 (enExample)
IL (1) IL255449B2 (enExample)
MX (1) MX379817B (enExample)
WO (1) WO2016179550A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984618C (en) 2015-05-07 2024-01-09 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
CA2984621C (en) * 2015-05-07 2023-09-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
WO2017211650A1 (en) * 2016-06-09 2017-12-14 Basf Se Substituted oxadiazoles for combating phytopathogenic fungi
US10757941B2 (en) * 2016-07-22 2020-09-01 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
WO2019219464A1 (en) 2018-05-15 2019-11-21 Basf Se Substituted trifluoromethyloxadiazoles for combating phytopathogenic fungi
KR102009034B1 (ko) 2019-01-31 2019-08-08 주식회사 아이스크림에듀 학습 분석을 기초로 정보를 제공하는 방법 및 시스템
KR102052844B1 (ko) 2019-01-31 2019-12-05 주식회사 아이스크림에듀 학습 분석 방법 및 시스템
KR102232343B1 (ko) 2019-12-11 2021-03-26 주식회사 아이스크림에듀 인공지능 기반 맞춤형 학습 방법 및 시스템
KR102191670B1 (ko) 2019-12-20 2020-12-16 주식회사 아이스크림에듀 문제은행 및 지식맵 기반 맞춤형 학습 방법 및 시스템
KR102191671B1 (ko) 2019-12-20 2020-12-16 주식회사 아이스크림에듀 소셜 러닝 및 e포트폴리오 기반 맞춤형 학습 방법 및 시스템
KR102197752B1 (ko) 2019-12-20 2021-01-04 주식회사 아이스크림에듀 맞춤형 자동 문항 생성을 통한 인공지능 기반 학습 방법 및 시스템
KR102191672B1 (ko) 2019-12-20 2020-12-16 주식회사 아이스크림에듀 학습 분석 및 인공지능 기반 맞춤형 학습 방법 및 시스템
KR102258234B1 (ko) 2020-02-27 2021-05-31 주식회사 아이스크림에듀 인공지능 가정교사 인터페이스가 적용된 맞춤형 학습 방법 및 시스템
KR102258235B1 (ko) 2020-02-27 2021-05-31 주식회사 아이스크림에듀 실감 콘텐츠가 적용된 인공지능 기반의 맞춤형 학습 방법 및 시스템
KR102232344B1 (ko) 2020-02-27 2021-03-26 주식회사 아이스크림에듀 빅데이터 및 인공지능 기반의 맞춤형 학습 방법 및 시스템
CN111190006A (zh) * 2020-03-09 2020-05-22 上海市东方医院（同济大学附属东方医院） 组蛋白去乙酰化酶6在制备用于评估维持性腹膜透析患者腹膜功能的标志物中的用途
KR102222533B1 (ko) 2020-06-25 2021-03-05 주식회사 아이스크림미디어 고정형 웹 콘텐츠를 반응형 콘텐츠로 자동 변환하는 시스템 및 그 제어방법
IL300389A (en) * 2020-08-07 2023-04-01 Italfarmaco Spa New oxadiazole-based selective HDAC6 inhibitors
KR102248960B1 (ko) 2020-08-19 2021-05-07 주식회사 아이스크림에듀 인공지능 학습 플랫폼을 이용한 비즈니스 방법 및 시스템
CN117430513A (zh) * 2023-10-27 2024-01-23 中昊(大连)化工研究设计院有限公司 环丙基胺的合成新方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2462341T3 (es) * 2004-12-10 2014-05-22 Msd Italia S.R.L. Derivados heterocíclicos como inhibidores de histona desacetilasas (HDAC)
GB0427138D0 (en) * 2004-12-10 2005-01-12 Angeletti P Ist Richerche Bio Therapeutic compounds
JP2013517281A (ja) * 2010-01-13 2013-05-16 テンペロ、ファーマシューティカルズ、インコーポレイテッド 化合物及び方法
WO2011088181A1 (en) 2010-01-13 2011-07-21 Tempero Pharmaceuticals, Inc. Compounds and methods
BR112014000371A2 (pt) 2011-07-08 2017-01-10 Novartis Ag derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
WO2013009830A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
WO2013009810A1 (en) 2011-07-13 2013-01-17 Tempero Pharmaceuticals, Inc. Methods of treatment
EA027451B1 (ru) * 2011-08-30 2017-07-31 Схди Фаундейшн, Инк. Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и их применение
MX2014006409A (es) * 2011-11-28 2014-07-30 Novartis Ag Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
CN104244939A (zh) * 2012-04-05 2014-12-24 Chdi基金会股份有限公司 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法
CA2984618C (en) 2015-05-07 2024-01-09 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
CA2984621C (en) * 2015-05-07 2023-09-26 Chdi Foundation, Inc. Histone deacetylase inhibitors and compositions and methods of use thereof
CN107980040B (zh) 2015-07-27 2021-11-26 株式会社钟根堂 作为组蛋白去乙酰酶6抑制剂的1,3,4-噁二唑磺酰胺衍生物及含其的医药组合物
MY197262A (en) 2015-07-27 2023-06-08 Chong Kun Dang Pharmaceutical Corp 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same
HRP20220003T1 (hr) 2015-08-04 2022-04-01 Chong Kun Dang Pharmaceutical Corp. Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013006408A1 (en) * 2011-07-01 2013-01-10 Tempero Pharmaceuticals, Inc. Compounds and methods

Also Published As

Publication number Publication date
IL255449B1 (en) 2023-03-01
AU2016256917A1 (en) 2017-11-23
US20160333001A1 (en) 2016-11-17
MX379817B (es) 2025-03-11
BR112017023710B1 (pt) 2023-03-07
CN107735087A (zh) 2018-02-23
HK1252489A1 (zh) 2019-05-24
EA035592B1 (ru) 2020-07-13
CA2984621C (en) 2023-09-26
EP3291809A1 (en) 2018-03-14
US20190185463A1 (en) 2019-06-20
BR112017023710A2 (pt) 2018-07-31
KR20180002730A (ko) 2018-01-08
MX2017014299A (es) 2018-08-09
CN107735087B (zh) 2021-09-03
EP3291809A4 (en) 2018-10-03
JP6782255B2 (ja) 2020-11-11
CA2984621A1 (en) 2016-11-10
EP3291809B1 (en) 2021-08-25
EA201792255A1 (ru) 2018-06-29
WO2016179550A1 (en) 2016-11-10
IL255449A0 (en) 2017-12-31
JP2018515492A (ja) 2018-06-14
AU2016256917B2 (en) 2021-08-26
US10047073B2 (en) 2018-08-14

Similar Documents

Publication Publication Date Title
EP3291809B1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US9783488B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP3291810B1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US20140163009A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US20160031863A1 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
US9505736B2 (en) Histone deacetylase inhibitors and compositions and methods of use thereof
EP2968207A1 (en) Histone deacetylase inhibitors and compositions
HK1252489B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
HK1252487B (en) Histone deacetylase inhibitors and compositions and methods of use thereof
BR112017023711B1 (pt) Inibidores de histona deacetilase e composições e métodos de uso dos mesmos